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Post-translational modification of proteins by ubiquitylation is increasingly recognised 
as a highly complex code that contributes to the regulation of diverse cellular 
processes. In humans, a family of almost one hundred deubiquitylase enzymes 
(DUBs) are assigned to six sub-families and many of these DUBs can remove 
ubiquitin from proteins to reverse signals. Roles for individual DUBs have been 
delineated within specific cellular processes, including many that are dysregulated in 
diseases, particularly cancer. As potentially druggable enzymes, disease-associated 
DUBs are of increasing interest as pharmaceutical targets. The biology, structure and 
regulation of DUBs have been extensively reviewed elsewhere, so here we focus 
specifically on roles of DUBs in regulating cell cycle processes in mammalian cells. 
Over a quarter of all DUBs, representing four different families, have been shown to 
play roles either in the unidirectional progression of the cell cycle through specific 
checkpoints, or in the DNA damage response and repair pathways. We catalogue 
these roles and discuss specific examples. Centrosomes are the major microtubule 
nucleating centres within a cell, and play a key role in forming the bipolar mitotic 
spindle required to accurately divide genetic material between daughter cells during 
cell division. To enable this mitotic role, centrosomes undergo a complex replication 
cycle that is intimately linked to the cell division cycle. Here we also catalogue and 
discuss DUBs that have been linked to centrosome replication or function, including 





The post-translational attachment of ubiquitin moieties to substrate proteins, termed 
ubiquitylation, involves the covalent conjugation of ubiquitin, most commonly to lysine 
(K) residues. In the simplest form, ubiquitylation is the addition of an ubiquitin 
monomer, termed monoubiquitylation. However, the ubiquitin signal can be highly 
complex and is linked to a plethora of cellular processes (1, 2). Polyubiquitin chains 
linked through K48 target proteins for proteasomal degradation. However, ubiquitin 
possesses seven lysine residues (K6, K11, K27, K29, K33, K48 and K63) enabling 
the formation of diverse polyubiquitin chains that may be homotypic or heterotypic in 
nature, and can have alternative functions, as comprehensively reviewed in (3). The 
world of ubiquitylation is multifaceted and each layer relies upon families of proteins 
to write, read or erase this ubiquitin code. The steps to write the ubiquitin code are 
highly conserved, relying on an E1 ubiquitin activating enzyme, an E2 ubiquitin 
conjugating enzyme and an E3 ubiquitin protein ligase with substrate specificity. As 
reviewed in (1), the human genome encodes two ubiquitin E1 enzymes, 
approximately forty E2 enzymes and more than six hundred E3 ligases, a clear 
depiction of the complexity involved in functional ubiquitylation. 
 
Ubiquitylation is a reversible post-translational modification, with removal of the 
ubiquitin signal catalysed by deubiquitylase enzymes (DUBs). The human genome 
encodes approximately one hundred DUBs, that we refer to here as the DUBome. 
These DUBs belong to six families: the ubiquitin specific protease (USP), ubiquitin C-
terminal hydrolase (UCH), ovarian tumour protease (OTU), Josephin (JOS), 
JAB1/MPN/MOV34 (JAMM) families (4), or the newly discovered motif-interacting 
with Ub (MIU)-containing novel DUB (MINDY) family (5). As reviewed in (4), whilst 
most DUB families are thiol proteases harbouring a catalytic triad, the JAMM 
metalloproteases require a zinc ion to facilitate ubiquitin chain removal. As editors of 
ubiquitin signalling, DUBs are regulators of varied essential cellular processes, 
notably many have been assigned roles in DNA damage repair and cell cycle 
progression. As these processes are often dysregulated in cancer, DUBs, as 
potentially druggable enzymes, have quickly become the focus of several 
pharmaceutical companies vying to develop new cancer therapies. 
 
The cell division cycle 
The cell cycle coordinates cellular events to duplicate the genetic material and divide 
the cellular contents to create two identical daughter cells. The cycle comprises four 
stages. After division, cells undergo an initial growth phase (G1), followed by the 
replication of the genome (S-phase). A second growth phase (G2) prepares the cell 
for division and assembles cytoskeletal structures, before the genetic material 
divides between the daughter cells during mitosis (M). The unidirectional progression 
through these cell cycle phases is dependent upon the periodic activation and 
inactivation of substrate proteins by kinases (including CDKs and PLKs) and 
ubiquitin-mediated degradation of key effectors by E3 ligases (including the APC/C 
and SCF complexes). Accordingly, cell cycle effectors are regulated through protein-
protein interactions, phosphorylation-dependent activation and ubiquitylation-
dependent degradation, all working in concert to achieve an exquisite level of control 
throughout the cycle (6). Once initiated, the cell cycle can be viewed as a series of 
autonomic cellular events that cascade until the eventual division into two daughter 
cells. However, checkpoints are inherent in the system, to temporarily halt the cell 
cycle if conditions are unfavourable. Many DUBs have direct or indirect roles during 
the cell cycle (7-9).  We discuss here selected examples of those regulating cell 
cycle progression and checkpoint maintenance, as summarised in Figure 1. 
 
DUBs and the G1 restriction point 
Upon entering G1, cells are not committed to a subsequent round of cell division, as 
entry into the cell cycle requires sufficient mitogenic signalling to overcome a 
restriction point in late G1. Rb, the mediator of this restriction point, inhibits the E2F 
transcription factor during G1 (10). Upon CDK4/6 activation by the G1-cyclin CCND 
and then by CCNE, Rb is increasingly phosphorylated. This results in progression 
through the restriction point as hyperphosphorylated Rb dissociates from E2F, 
causing the transcription of S-phase genes (importantly CCNE and CCNA) (11). In 
addition to phosphorylation, Rb is regulated by ubiquitylation, being a target of the E3 
ligase MDM2 (12, 13) which promotes its proteasomal degradation (14). The DUB 
USP7 directly antagonises MDM2-mediated polyubiquitylation of Rb, stalling the cell 
cycle in G1 (15). USP7 is not the only DUB that may govern the restriction point, the 
tumour suppressor BAP1 also indirectly regulates the activity of E2F, via the 
deubiquitylation of HCF-1, an important transcriptional co-regulator at E2F promoter 
sites (16, 17). CYLD, another well-established tumour suppressor, plays a protective 
role during G1 via the transcription factor BCL-3. CYLD deubiquitylates BCL-3 
inhibiting its nuclear translocation and so decreases the transcription of BCL-3 target 
genes including CCND (18). CYLD therefore indirectly decreases CCND levels 
preventing cells from passing through the restriction point. During G1, the APC/C 
polyubiquitylates the S-phase cyclin CCNA, targeting it for degradation in order to 
prevent the cell from entering S-phase. The DUB USP37 directly regulates S-phase 
entry through antagonising activity of the APC/CCDH1 in G1 by removing polyubiquitin 
chains to stabilise CCNA (19). 
 
DUBs and DNA damage checkpoints  
Key to successful cell division is maintaining the integrity of the genome during DNA 
replication in S-phase, and this is monitored by a number of quality control 
mechanisms. If DNA becomes damaged, checkpoints stall the cell cycle and activate 
DNA damage repair (DDR) pathways. This response revolves around p53, which is 
stabilised and activated by DNA damage checkpoint signalling following a range of 
genotoxic insults. Under normal conditions, p53 is continuously synthesized but 
maintained at a low level by MDM2 polyubiquitylation targeting p53 for proteasomal 
degradation (20). Under genotoxic stress, these regulatory mechanisms are 
reversed, to allow p53 to stall the cell cycle to enable repair or trigger apoptosis. At 
sites of DNA damage, sensors (e.g. 53BP1) facilitate the activation of DNA damage 
kinases (notably ATM and CHK2) resulting in p53 phosphorylation. This abolishes 
the interaction between p53 and MDM2, increasing p53 levels and inducing 
transcription of p53 target genes (21), as well as activating transcription-independent 
roles of p53 in many of the major DDR pathways (22).  
 
Given the integral role of p53 in cell cycle fate, it is perhaps unsurprising that many 
DUBs have been highlighted as direct or indirect p53 regulators, including USP2a, 
USP5, USP7 (HAUSP), USP10, USP11, USP28, OTUB1 and OTUD5. USP7, a 
predominantly nuclear DUB, was the first to be associated with the p53-dependent 
DDR via directly antagonising MDM2 polyubiquitylation of p53 (23). However, USP7 
also directly deubiquitylates the auto-polyubiquitylated MDM2, stabilising the E3 
ligase as well as its substrate (24). Although this may seem counterintuitive, USP7 
exhibits a preference for MDM2 over p53 in unstressed cells ensuring p53 levels are 
maintained at a low level. Upon DNA damage, USP7 is dephosphorylated by PPM1G 
reducing activity towards MDM2, leading to increased auto-polyubiquitylation and 
degradation of MDM2, and the subsequent accumulation of p53 (25).  
 
Other DUBs, including USP10, USP11 and OTUD5, also directly interact with, 
deubiquitylate and stabilise p53. Interestingly USP10, a predominantly cytoplasmic 
DUB, is involved in homeostasis of cytoplasmic p53 in unstressed cells, but following 
DNA damage a fraction of USP10 can translocate into the nucleus where it 
contributes to p53 activation (26). As described for USP7, other DUBs indirectly 
control p53 levels via MDM2. For example, USP2a negatively regulates p53 levels 
through the stabilisation of MDM2, whilst exhibiting no deubiquitylating activity 
towards p53 directly (27). OTUB1, another cytoplasmic DUB, can directly interact 
with p53, but predominantly stabilises p53 indirectly in the cytoplasm, through a non-
catalytic mechanism.  OTUB1 does this by binding and supressing polyubiquitylation 
through the MDM2 associated E2 enzyme UbcH5 (28). In contrast, USP28 was 
shown to interact with and stabilise both the damage sensor 53BP1 and the 
checkpoint kinase CHK2, that activate p53 under genotoxic conditions (29). USP5 
uses perhaps the most indirect mechanism to stabilise p53 without physically 
interacting with components of the p53-MDM2 axis. It primarily disassembles 
unanchored polyubiquitin chains, and loss of USP5 results in accumulation of these 
chains that compete with ubiquitylated p53, but not MDM2, for proteasome 
recognition and degradation so that p53 is selectively stabilised (30).  
 
In addition, many DUBs have also been associated with executing specific DDR 
pathways (8).  For example, USP1 can support repair through both the Fanconi 
anaemia and translesion repair pathways (31). An RNAi-based study has linked 
USP3 with double-strand DNA break repair; USP3 directly interacts with and 
removes monoubiquitylation from histones H2A and H2B, and possibly other DDR 
effectors, to coordinate DNA repair (32). Some DUBs exhibit a more global effect on 
DDR pathways, for example one screen revealed that UCHL5 was recruited to sites 
of DNA damage in addition to being involved in double-strand break resection (33). 
 
DUBs with roles in mitotic progression and cytokinesis 
Following replication of the genome, and assuming checkpoints are satisfied in G2, 
the cell enters mitosis, where the newly replicated sister chromatids must be divided 
into each daughter cell. To achieve this, the cell passes through a sequence of 
distinct mitotic phases: prophase, metaphase, anaphase, telophase and cytokinesis 
(Figure 1). Prior to mitosis, the mitotic kinase CDK1 is held in an inactivate state by 
WEE1 phosphorylation, until SCFβTrCP-mediated ubiquitylation and degradation of 
WEE1 triggers mitotic entry; USP50 can repress mitotic entry through stabilising 
WEE1 (34).  Subsequently, USP7 can indirectly regulate the levels of Aurora A, a 
kinase required for correct maturation of the bipolar mitotic spindle, by stabilising 
CHFR, an E3 ligase that targets Aurora A for degradation (35).  
 
USP44 was one of the first DUBs to be linked to mitotic progression, with a role in 
metaphase-anaphase transition (36). Anaphase entry is stimulated by the APC/C 
and results in the separation of sister chromatids. To ensure the correct chromosome 
complement is distributed to each daughter cell, the spindle assembly checkpoint 
(SAC) monitors attachment of each chromosome pair to opposite poles of the mitotic 
spindle. Anaphase is arrested until the SAC is satisfied, preventing premature and 
inaccurate division of genomic content. Three key proteins, MAD2, BUBR1 and 
BUB3, comprise the mitotic checkpoint complex (MCC) (37). The MCC sequesters 
the APC/C activator CDC20 at unattached chromosomes, thus inhibiting the APC/C 
until chromosomes are correctly attached (37). Once the SAC is satisfied, CDC20 is 
ubiquitylated and subsequently dissociates from the MCC to activate the APC/C (38). 
USP44 plays a protective role at the SAC, directly antagonising CDC20 
ubiquitylation, and so promoting MCC inhibition of the APC/C (36). Once the SAC is 
satisfied, USP44 dephosphorylation decreases its activity towards CDC20, initiating 
mitotic exit through APC/C activation (39). 
 
USP44 is not the only DUB that contributes to regulation of the SAC, for example 
USP39 and USP9X are also essential for the correct alignment of chromosomes at 
the mitotic spindle and their accurate division during anaphase. The mitotic kinase 
Aurora B is a key regulator of the attachment of sister chromatids to microtubules in 
the mitotic spindle.  It exists in a complex with Survivin, the ubiquitylation status of 
which mediates interaction of the complex with chromosomes (40). Depletion of 
USP39 results in decreased transcription and consequently lower levels of Aurora B 
kinase in cycling cells (41), whilst USP9X-mediated deubiquitylation of Survivin is 
required for dissociation from the chromosomes once correctly aligned (42). Another 
DUB, USP4, plays an indirect role in the SAC through regulating correct splicing of 
mRNA transcripts, including for the mitotic checkpoint kinase BUB1 (43).  
 
The DUB CYLD plays roles during both metaphase and cytokinesis. CYLD directly 
interacts with the catalytic domain of HDAC6, inhibiting alpha-tubulin deacetylation 
and therefore indirectly increasing the stability of microtubules. This governance of 
microtubule stability by CYLD plays a role in spindle orientation during metaphase 
(44) and regulates the rate of cytokinesis (45). Lastly, USP8 and AMSH, two DUBs 
that are usually recruited to endosomes, have an important role in cytokinesis. The 
scission of the two daughter cells requires components of the ESCRT machinery 
including VAMP8, which co-localises with, and is deubiquitylated by, both USP8 and 




The centrosome cycle 
Centrosomes are cytoplasmic organelles which act as the dominant microtubule-
organizing centres (MTOCs) in animal cells. During the cell cycle, centrosomes 
determine spatial arrangement of the microtubule arrays to influence cell shape, 
polarity, motility and organization of the mitotic spindle (47, 48). The core 
components are two centrioles, small barrel-shaped organelles that are embedded in 
pericentriolar material (PCM). Each centriole consists of nine microtubule triplets 
arranged in a highly conserved rotational symmetry, imparted by SAS-6 during 
centriole assembly (49, 50). The PCM is a dense protein matrix composed of various 
proteins and exhibiting a high level of spatial organization, its major function is 
recruitment of gamma-tubulin complexes which are essential for microtubule 
nucleation (51, 52). 
 
Centrosome replication is strictly coordinated with cell cycle progression (Figure 2). 
Duplication of the single G1 centrosome begins at the G1/S transition and is 
completed during S-phase so that two centrosomes are present in G2. These 
facilitate bipolar spindle formation at metaphase and are then segregated, one into 
each daughter cell, during cytokinesis (53, 54). Key to centrosome replication is 
centriole duplication, as the pre-existing mother centriole duplicates itself to form a 
daughter centriole. The kinase PLK4 and two SCF ubiquitin E3 ligases ensure that 
only a single replication event normally occurs. SCFFBXW5 ubiquitylates SAS-6 to 
target it for proteasomal degradation, preventing centriole over-duplication. SCFFBXW5 
activity is limited by PLK4 to prevent premature SAS-6 degradation. Following G1/S 
transition, PLK4 homodimerises and trans-autophosphorylates, signalling recruitment 
of SCFβTrCP which ubiquitylates and degrades PLK4. Decreased PLK4 levels restore 
SCFFBXW5 activity and block re-duplication (49, 55-58). Once duplicated, the daughter 
centriole elongates during S-phase and G2. This process is controlled by several 
genes including the multifunctional centriolar protein CP110, which becomes 
ubiquitylated by SCFcyclinF during G2 and mitosis. Centrosomes then undergo a 
maturation process which requires recruitment of PCM.  Finally, the centrosomes 
separate during G2, through KIF11 kinesin activity, which also facilitates bipolar 
spindle formation during mitosis (49, 59, 60).   
 
Many human cells also display cilia in a cell cycle-dependent manner. During G1 (or 
G0 in terminally-differentiated cells) centrosomes migrate to the cell cortex, where the 
mother centriole matures into a basal body which acts as a template for cilia 
elongation. During S-phase, both mother and daughter centrioles undergo 
duplication as normal. Then, prior to mitosis, cilia disassemble and the centrioles 
migrate back to the cell interior, ready to act as spindle poles during mitosis (61). 
 
Various cell division errors, such as centrosome over-duplication, cytokinesis failure, 
or cell fusion can cause centrosome amplification, which is observed in many human 
cancers. The notion that, in addition to acting as MTOCs, centrosomes may function 
as signalling hubs (62) suggests one way in which amplification of centrosomes may 
benefit cancer cells.  However, supernumerary centrosomes may cause multipolar 
spindle formation, impaired cell division, aneuploidy and genomic instability (63, 64). 
If uncorrected, multipolar spindles can lead to multipolar cell division and massive 
aneuploidy, which is usually lethal for the cell. Some cancer cells use mechanisms 
such as centrosome inactivation or centrosome loss to avoid multipolar divisions 
(65). However, centrosome clustering is probably the most common response in 
cancer cells; this enables aggregation of additional centrosomes into two groups to 
form a pseudo-bipolar spindle and allow the cell to undergo bipolar cell division (66, 
67). Ubiquitylation is increasingly recognised as a key regulator of centrosome 
biology (68), and our current knowledge of the role for DUBs in specific aspects of 
the centrosome cycle is summarised in Figure 2. 
 
DUBs regulating centrosome duplication and elongation during S/G2 
During S-phase centrosomes must be duplicated exactly once. A number of the key 
proteins involved in centrosome duplication are ubiquitylated and therefore also open 
to regulation by deubiquitylation; the balance between these processes is imperative 
for precise duplication. For example, CP110 levels are normally tightly controlled 
during G2 and mitosis through ubiquitylation by SCF
cyclinF, leading to CP110 
degradation (69). Countering this, USP33 localises to centrioles during S-phase and 
G2/M where it can deubiquitylate and stabilise CP110. Overexpression of either 
CP110 (70) or USP33 (71) leads to centrosome amplification. Similarly, appropriate 
expression of CEP131, a centriolar satellite protein, is required for accurate 
centrosome duplication (72). Affinity purification and mass spectrometry identified 
USP9X as a CEP131 interactor (73); USP9X localizes to centrosomes in a cell cycle-
dependent manner, most strikingly during S-phase and G2. USP9X gain-of-function 
leads to CEP131 deubiquitylation, stabilization and centrosome amplification (73). In 
addition, overexpression of a third DUB, USP1, is also linked with centrosome 
amplification. Although the mechanism remains unclear, USP1 may act in part 
through increasing expression of ID1 (74), a fraction of which localises to the 
centrosome, as ID1 overexpression can induce centrosome amplification (75). 
 DUBs affecting centrosome maturation, separation and mitotic spindle 
organisation during G2 and mitosis 
BRCA1/BARD1-dependent ubiquitylation of gamma-tubulin plays a key role in the 
regulation of centrosome duplication and microtubule nucleation, with BRCA1 loss 
resulting in centrosome amplification (76, 77). An siRNA screen for DUBs that affect 
levels of ubiquitylated gamma-tubulin identified BAP1 and UCHL1 as candidates 
(78). Whilst UCHL1 interacts with gamma-tubulin in G1, the BAP1 interaction is 
largely confined to mitosis, suggesting these two DUBs regulate gamma-tubulin in a 
cell cycle-dependent manner (78). BAP1 removes ubiquitin from gamma-tubulin, and 
mitotic defects in cells with low BAP1 levels are rescued by expression of BAP1 but 
not a catalytically inactive mutant. Whilst the mechanism remains to be fully 
elucidated, it seems deubiquitylation of gamma-tubulin by BAP1 during mitosis 
allows proper spindle organisation and function (78). CEP192 is a centrosomal 
protein with roles in maturation of centrosomes at the onset of mitosis and 
organization of the mitotic microtubule landscape. Mass spectrometry identified the 
deubiquitylase CYLD as a CEP192 interactor and CYLD co-depletion restores 
spindle assembly defects in CEP192-depleted cells (79).  
 
In addition to its well described role in the spindle-assembly checkpoint (36), USP44 
also independently affects mitotic geometry by regulating centrosome separation and 
positioning (80). USP44 interacts with CETN2 and, although the targets of USP44 at 
the centrosome remain to be elucidated, catalytically-inactive or CETN2-binding 
mutants of USP44 fail to rescue centrosome positioning defects. USP7 also plays a 
role in maintaining the correct number of centrosomes in a cell. It interacts with and 
stabilises centrosomal PLK1-phosphorylated 53BP1 at mitosis (81). Depletion of 
53BP1 results in lower levels of p53 and CENPF which is required for proper 
centrosome separation and spindle formation. Cells lacking 53BP1 accumulate 
supernumerary centrosomes, not through de novo amplification but rather due to 
failure of cytokinesis in cells with incorrect centrosome and spindle positioning and 
chromosomal missegregation. In contrast, USP37 depletion indirectly results in 
centrosome fragmentation, and hence multipolar spindle formation, through 
ubiquitylation and degradation of WAPL, a regulator of sister chromatid resolution 
and spindle tension (82). Notably, three recent papers have revealed a novel 
checkpoint, the mitotic surveillance pathway, that can detect centrosome loss or 
prolonged mitosis and results in cell cycle arrest (83-85). The signalling pathway 
involves 53BP1 and the deubiquitylase USP28 acting in a complex to deubiquitylate 
and stabilise p53, which in turn controls cell fate. 
 
DUBs involved in centrosome clustering during cancer cell mitosis 
Centrosome clustering is a mechanism that cancer cells containing supernumerary 
centrosomes commonly use to gather amplified centrosomes into two poles during 
mitosis, allowing for bipolar division and cancer cell proliferation (86). Inhibition of 
centrosome clustering is an attractive, cancer specific, therapeutic intervention. Two 
genome-wide screens have identified proteins required for centrosome clustering in 
Drosophila or human cells (87, 88). Analysis of the Drosophila dataset reveals 
prominence of proteins involved in ubiquitylation and the proteasomal pathway, 
including two DUBs, the Drosophila orthologues of human USP8 and USP31 (87). 
The screen in human cells also identified USP54 (88), a DUB that is predicted to be 
catalytically inactive (89). However, neither the ubiquitylation process nor these 
DUBs were investigated further in either study. In relation to its role in stabilising 
CP110 described above, USP33 may also indirectly affect centrosome clustering. 
Inhibition of CDK2 prevents CP110 phosphorylation that is required for centrosome 
clustering activity (90, 91) and combining CDK2 inhibition with USP33 depletion has 
a co-operative effect on CP110, driving anaphase catastrophe via multipolar spindle 
formation (91). In addition, the functional overlap of other DUBs with centrosome 
regulation makes it likely there are further DUBs involved in this process. For 
example, a functional SAC is required for effective centrosome clustering (87) and, 
as discussed above, several DUBs including USP4, USP9X, USP39 and USP44 are 
required for SAC activity (36, 41-43). 
 
DUBs involved in ciliogenesis during G0/G1 
A number of DUBs have been found to be required for the formation of primary cilia 
during G0/G1 phase of the cell cycle, a process termed ciliogenesis. Firstly, the DUB 
CYLD is recruited to centrosomes and the basal body of cilia via its interaction with 
CAP350, where it has to be present and catalytically active to promote docking of 
basal bodies at the plasma membrane and hence ciliogenesis (92). A concurrent 
study also demonstrated that CYLD is required for docking of basal bodies at the 
plasma membrane and identified that this can, at least in part, be explained by its 
ability to deubiquitylate CEP70. Deubiquitylation of CEP70 allows it to interact with 
gamma-tubulin at the centrosome to mediate ciliogenesis (93). In addition, CYLD 
inactivates HDAC6, which modulates cilia length (93). Secondly, via an independent 
mechanism to its roles in centrosome duplication, USP9X also regulates ciliogenesis 
(94). During G0/G1, USP9X is recruited to the centrosome where it deubiquitylates 
and stabilises NPHP5, a positive regulator of ciliogenesis, so favouring cilia 
formation. However, at G2/M USP9X becomes cytoplasmic, allowing degradation of 
NPHP5 and loss of cilia.  Lastly, a survey of DUB subcellular localisation found that 
USP21 localised to centrosomes and microtubules (95). USP21 is required for 
effective microtubule regrowth from centrosomes, neurite outgrowth, generation of 
the primary cilium (95), and hedgehog signalling (96). 
 
Conclusions, future challenges and outlook 
Here we highlight specific roles for many different DUBs in controlling critical aspects 
of cell cycle progression, p53 homeostasis and DNA damage repair, as well as 
centrosome biology. To date, at least 30% of the DUBome has been associated with 
these processes, with predominant representation from the USP and UCH families. 
In addition to these roles, it is evident that many other DUBs regulate cellular 
processes during specific cell cycle phases.  One example is the role of USP15 in 
regulating the transcriptional repressor REST. Like many transcription factors, REST 
is rapidly degraded at G2/M prior to cell division, however as it represses cellular 
differentiation genes it must be reconstituted in G1.  REST degradation is triggered by 
phosphorylation-dependent SCFβTrCP ubiquitylation (97, 98), and whilst this is 
reported to be antagonised by USP7 in neural progenitors (99), in cycling cells 
mitotic REST degradation appears to be unopposed. However, as cells exit mitosis, 
USP15 acts to deubiquitylate newly synthesized REST and rapidly rescue its 
expression levels (100). Considering phase-specific roles such as this greatly 
expands the involvement of the DUBome in cell cycle biology. 
 
This review aims to capture the current state of the field of DUB cell cycle research, 
but many outstanding questions remain. Whilst certain DUBs have very distinct roles, 
others like CYLD, USP9X and USP7, play multiple roles at various phases of both 
the cell and centrosome cycles.  Often we do not yet know how the function of a 
particular DUB is restricted to a cell cycle phase, or directed towards a specific 
target, to achieve precise temporal regulation of cell cycle effectors.  Indeed, 
although transcriptomics suggest USP1 is the only DUB that is periodically 
transcribed during the cell cycle (101), proteomics reveals periodic phosphorylation 
of several DUBs (102), but we at present lack a clear profile of regulated protein 
expression and activity for the DUBome during the cell cycle.   
 
Although certain DUBs, OTUB1 being a notable example (28), play important roles 
through scaffolding interactions independent of their catalytic activity, most DUBs 
have catalytic functions.  As highlighted in a recent review (103), unrestricted 
enzymatic activity of the DUBs would be hazardous for cells, and we are now 
beginning to appreciate the multi-layered mechanisms by which their activity can be 
controlled and directed.  These include internal regulatory domains within some 
DUBs, interaction with allosteric regulators, incorporation into macromolecular 
complexes, and post-translational modifications.  Relevant examples for stabilisation 
of p53 in response to genotoxic stress include phosphorylation-dependent nuclear 
localization of USP10 (26) and modulation of USP7 activity towards MDM2 (25). 
Intriguingly, allosteric activation of USP7 by GMPS that stabilizes alignment of the 
catalytic site can also direct USP7 activity towards p53 under genotoxic stress (104, 
105).  These findings begin to rationalise the physiological roles of a DUB that is 
capable of stabilising both p53 and the E3 ligase MDM2, which targets p53 for 
degradation.  
 
Another open question is why for certain processes, most notably in p53 regulation, 
there appears to be huge redundancy with multiple DUBs playing similar roles. One 
potential explanation is the ability of different DUBs to regulate p53 by different 
mechanisms and in different cellular compartments, as described above for USP7, 
USP10 and OTUB1.  This may help ensure fine control of p53 activation in response 
to genotoxic stress.  Critical roles for many DUBs have also been described in 
regulating the sharp and irreversible signalling decisions that are made at the G1 
restriction point and the SAC. In both cases, a picture is emerging where DUBs 
contribute to a regulatory network, and each key component of the cascade is 
controlled by a specific DUB. 
 
There is emerging interest in the role of the DUBome in centrosome biology, which 
less well studied than in the cell cycle..  As a distinct organelle, it is easier to 
visualise how temporal roles for DUBs may be regulated, with some DUBs such as 
USP33 (71), USP9X (73) and BAP1 (78) already known to be recruited to the 
centrosome in a cell cycle-dependent manner.  Where DUBs have been associated 
with the centrosome cycle, their mechanistic roles are often not yet well elucidated.  
For example, screens suggest that USP8 and USP31 may be linked to the 
centrosome clustering in Drosophila (87) and USP54 in human cells (88).  However, 
their centrosome-associated targets remain unknown, and no mechanism of action 
for these DUBs in regulating centrosome clustering has yet been suggested.  It will 
be interesting to see whether DUBs predicted from screens and in model organisms 
do play significant roles in centrosome clustering in human cancer cells.  Lastly, in 
addition to acting as MTOCs, centrosomes have recently also been established as 
signalling hubs (62). Many of the studies on DUBs at centrosomes we have 
discussed focus on their roles in duplicating and regulating the centrosome structure, 
and on their functions in nucleating microtubules. In future it is likely that new roles 
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53BP1, p53-binding protein 1; AMSH, Associated molecule with the SH3 domain of 
STAM; APC/C, anaphase promoting complex/cyclosome; BAP1, BRCA1-associated 
protein 1; ATM, Ataxia telangiectasia mutated; BARD1, BRCA1-associated RING 
domain protein 1; BCL-3, B-cell lymphoma 3 protein; BRCA1, Breast cancer type 1 
susceptibility protein; βTrCP, beta-transducin repeat containing protein; BUB3, 
Mitotic checkpoint protein BUB3; BUBR1, Mitotic checkpoint serine/threonine-protein 
kinase BUB1 beta; CAP350, Centrosome-associated protein of 350 kDa; CCNA, 
cyclin-A; CCND, cyclin-D; CCNE, cyclin-E; CDC20, Cell division cycle protein 20 
homolog; CDH1, CDC20 homolog 1; CDKs, cyclin-dependent kinases; CENPF, 
Centromere protein F; CEP70, Centrosomal protein of 70 kDa; CEP131, 
Centrosomal protein of 131 kDa; CEP192, Centrosomal protein of 192 kDa; CETN2, 
Centrin2; CHFR, Checkpoint with Forkhead and Ring Finger; CHK2, checkpoint 
kinase 2; CP110, Centriolar coiled-coil protein of 110 kDa; CYLD, Ubiquitin carboxyl-
terminal hydrolase Cylindromatosis; DDR, DNA damage repair; DUBs, 
deubiquitylases; DUBome, the cellular complement of DUBs; ESCRT, Endosomal 
sorting complexes required for transport; FBXW5, F-box/WD repeat-containing 
protein 5; H2A, Histone 2A; H2B, Histone 2B; HCF-1, Host cell factor 1; HDAC6, 
histone deacetylase 6; ID1, Inhibitor of DNA binding 1; JAMM, JAB1/MPN/MOV34; 
JOS, Josephin; KIF11, Kinesin-related motor protein Eg5; MAD2, Mitotic arrest 
deficient 2-like protein 1; MCC, mitotic checkpoint complex; MDM2, E3 ubiquitin-
protein ligase Mdm2 (Double minute 2 protein); MINDY, motif-interacting with Ub 
(MIU)-containing novel DUB; NPHP5, Nephrocystin-5/IQ calmodulin-binding motif-
containing protein 1; MTOCs, microtubule organizing centres; OTU, ovarian tumour 
protease; p53, Cellular tumour antigen p53; PCM, pericentriolar material; PLKs, polo-
like kinases; PPM1G, Protein phosphatase 1G; Rb, retinoblastoma protein; SAC, 
spindle assembly checkpoint; SAS-6, Spindle assembly abnormal protein 6 homolog; 
SCF, skp/cullin/F-box; UbcH5, Ubiquitin-Conjugating Enzyme E2D 1 (UBC4/5 
Homolog, Yeast); UCH, ubiquitin C-terminal hydrolase; USP, ubiquitin specific 
protease; VAMP8, Vesicle-associated membrane protein 8; WAPL, Wings apart-like 
protein homolog; WEE1, WEE1 G2 Checkpoint Kinase. 
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Figure 1. DUBs associated with the cell cycle. 
The cell cycle is schematically represented, highlighting key checkpoints and the 
individual stages of mitosis.  DUBs with specific roles are indicated in the appropriate 
phases: solid colouring shows membership of the DUB families, and coloured edges 
illustrate the major cell cycle function.  SAC: spindle assembly checkpoint. 
 
Figure 2. DUBs associated with the centrosome cycle. 
The cell cycle is schematically represented, highlighting the key stages of 
centrosome replication and function.  DUBs with specific roles are indicated in the 
appropriate phases: solid colouring shows membership of the DUB families, and 
coloured edges illustrate the major function in the centrosome cycle. 
 
 


